



Ambrosia Biosciences

July 2026

Ambrosia is developing orally available small-molecule therapies targeting GLP-1 and related receptors for safe, effective, affordable metabolic treatment, enabling combination and personalized patient care.

Why Oral Small Molecules?



Peptides - Inherent Delivery and Scaling Challenges:

- **Poor oral bioavailability** typically necessitates injection - limiting patient adoption and adherence
- Oral versions require large doses and offer **inconsistent performance** in real world
- **Manufacturing** is complex and resource-intensive
- Delivery devices **increase cost and waste**
- **Cold-chain requirement** hampers distribution, particularly at global scale



Small Molecules - Patient-Friendly Delivery with Scalable Economics:

- **Oral dosing preferred** by patients and supports flexible, personalized titration
- **Scalable, lower COGs** manufacturing
- **Stable** at room temperature
- **No delivery device**; less waste

Oral Small Molecule Discovery Pipeline

GLP-1R Agonist
QD Dosing

DC/IND-enabling studies

Developing a differentiated GLP-1 molecule demonstrating best-in-class potential, based on a novel structural approach and emphasis on lower effective human dosing, superior 24-hour target coverage, and improved combinability.

GLP-1R Agonist
QW Dosing

Discovery

Extended half-life to enable once weekly dosing, while maintaining performance differentiation attributes of daily GLP-1R agonist.

GIPR Antagonist

Discovery

Combination dosing with GLP1-RA to amplify efficacy while maintaining tolerability, as well as potential for maintenance dosing.

Amylin Agonist

Discovery

Once daily monotherapy or in combination with synergistic therapies, such as GLP-1RA.

Ambrosia Snapshot

Proven drug discovery team from 

Investors:

BVF Partners, Boulder Ventures, Blue Owl Healthcare Opp, Deep Track, Redmile, Janus, Samsara and Merck

Team:

- Founding scientific team with a proven track record in all stages of structure-based drug discovery
- Contributed to *30 IND filings on 25 NMEs and 7 FDA approvals*

Boulder, CO Facilities (24,000 sq. ft.):

- **Fully integrated chemistry & biology operations** enabling rapid iteration
- **NMR, structural biology, & AI-enabled molecular design** supporting GPCR discovery
- **BSL-2 & in vitro ADME labs** for rapid preclinical screening

Ambrosia Team

Experienced drug developers and company builders



Nick Traggis
Founder and CEO



Patrice Lee, PhD
President, R&D



Linda Shapiro
Manning, M.D., Ph.D.
Chief Medical Officer



Erik Hicken, PhD
Head of Chemistry



Andrea Flynn, PhD
Chief Business Officer



Faraz Naqvi, MD
Founder, Medical Director




Ben Carver
Founder, General Counsel



Kenny Edwards
Vice President, Finance



Ambrosia Timeline





Ambrosia
Biosciences

Contact:
info@ambrosia.health